<DOC>
	<DOCNO>NCT02216084</DOCNO>
	<brief_summary>The purpose Phase 1 , prospective , uncontrolled , open-label , multicenter , dose-escalation study evaluate safety , include immunogenicity , pharmacokinetics BAX930 ( rADAMTS13 ) total 14 evaluable subject diagnose severe hereditary thrombotic thrombocytopenic purpura ( TTP ) ( plasma ADAMTS13 activity &lt; 6 % ) assign one three dose cohort .</brief_summary>
	<brief_title>Phase 1 Dose Escalation , Single Dose Study Assess Safety Pharmacokinetics BAX930 Hereditary Thrombotic Thrombocytopenic Purpura ( TTP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<criteria>Subject 12 65 year age , inclusive . ( The first 2 subject cohort ≥ 18 year age . ) Subject and/or legally authorize representative provide write informed consent . Subject documented diagnosis severe hereditary ADAMTS13 deficiency , define 1 ) confirm genetic testing , document patient history screening , 2 ) ADAMTS13 activity &lt; 6 % , documented patient history screening . NOTE : In patient receive prophylactic therapy fresh frozen plasma ( FFP ) ADAMTS13 contain product , level plasma ADAMTS13 activity may exceed 6 % screening . Cryoprecipitate , FFP , ADAMTS13 contain product interfere ADAMTS13 PK pause least 10 day prior infusion investigational product . The subject display severe TTP symptom screen . Patients present minor , stable laboratory abnormality ( LDH high 3 time upper limit normal ; platelet count low 100,000 per μl ) screening may enrol . Subjects ≥18 year age Karnofsky score ≥ 60 % , subject &lt; 18 year age Lansky score ≥ 70 % . Subject hepatitis C virus negative ( HCV ) confirm antibody polymerase chain reaction ( PCR ) testing ; HCV positive ( HCV+ ) subject eligible inclusion disease chronic stable . If female childbearing potential , subject present negative serum pregnancy test agree employ adequate birth control measure duration study . Subject willing able comply requirement protocol . Subject diagnose TTPlike disorder ( example , microangiopathic hemolytic anemia ) , include acquire TTP . Subject known hypersensitivity hamster proteins component investigational product . Subject medical history presence functional neutralizing ADAMTS13 inhibitor screen . Subject medical history immunological disorder , exclude seasonal allergic rhinitis/conjunctivitis/mild asthma , food allergy animal allergy . Subject medical history hematological disorder , particular systemic lupus erythematosus , amyloidosis , antiphospholipid antibody syndrome , vasculitis , hemolytic anemia , disseminate intravascular coagulation , systemic scleroderma . Subject history significant neurological event , major stroke , indicate relapse might severe consequence , judge investigator . Subject HIV positive absolute CD4 count &lt; 200/mm3 . Subject diagnose cardiovascular disease [ New York Heart Association ( NYHA ) class 34 ] . Subject schedule undergo elective surgery study participation . Subject diagnose severe liver disease , evidence , limited , follow : serum ALT 3 time upper limit normal , international normalize ratio ( INR ) &gt; 1.5 , hypoalbuminemia , portal vein hypertension ( e.g . presence otherwise unexplained splenomegaly , history esophageal varix ) . Subject diagnose severe glomerular disease , gross proteinuria serum creatinine level ≥ 2.5 mg/dL . Subject treated immunomodulatory drug , case corticoid equivalent hydrocortisone great 10 mg /day , exclude topical treatment ( e.g . ointment , nasal spray ) , within 30 day prior enrollment . Subject history drug and/or alcohol abuse within last 6 month prior study enrollment . Subject life expectancy le 3 month . Subject identify investigator unable unwilling cooperate study procedure . Subject family member employee investigator . Subject suffers mental condition render him/her unable understand nature , scope possible consequence study and/or evidence uncooperative attitude . If female , subject pregnant lactating time study enrollment . Subject participate another clinical study involve investigational product device within 30 day prior study enrollment . Subject schedule participate another clinical study involve investigational product device course study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>